Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit–risk assessment
BackgroundOptimal second-line systemic therapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study compared the efficacy and safety of available second-line treatments after tyrosine kinase inhibitor (TKI) failure and explored tre…